Objective. To introduce a novel preclinical animal model of psoriatic arthritis (PsA) in R26Stat3C stopfl/fl CD4Cre mice, and to investigate the role of Th17 cytokines in the disease pathogenesis.
Objective. To introduce a novel preclinical animal model of psoriatic arthritis (PsA) in R26Stat3C stopfl/fl CD4Cre mice, and to investigate the role of Th17 cytokines in the disease pathogenesis.
Methods. We characterized a novel murine model of Th17-driven cutaneous and synovio-entheseal disease directed by T cell-specific expression of a hyperactive Stat3 allele. By crossing R26Stat3C stopfl/fl CD4Cre mice onto an interleukin-22 (IL-22)-knockout background or treating the mice with a neutralizing antibody against IL-17, we interrogated how these Th17 cytokines could contribute to the pathogenesis of PsA.
Results. R26Stat3C
stopfl/fl CD4Cre mice developed acanthosis, hyperkeratosis, and parakeratosis of the skin, as well as enthesitis/tendinitis and periarticular bone erosion in different joints, accompanied by osteopenia. T cell-specific expression of a hyperactive Stat3C allele was found to drive the augmented Th17 response in these animals. Careful characterization of the mouse bone marrow revealed an increase in osteoclast progenitor (OCP) and RANKL-producing cells, which contributed to the osteopenia phenotype observed in the mutant animals. Abrogation of the Th17 cytokines IL-17 or IL-22 improved both the skin and bone phenotype in R26Stat3C stopfl/fl CD4Cre mice, revealing a central role of Th17 cells in the regulation of OCP and RANKL expression on stromal cells.
Conclusion. Perturbation of the IL-23/Th17 axis instigates Th17-mediated inflammation in R26Stat3C stopfl/fl CD4Cre mice, leading to cutaneous and synovio-entheseal inflammation and bone pathologic features highly reminiscent of human PsA. Both IL-17A and IL-22 produced by Th17 cells appear to play critical roles in promoting the cutaneous and musculoskeletal inflammation that characterizes PsA.
Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by the presence of psoriasis and concomitant spondyloarthritis, affecting 2.5 million people in the United States (1) . In a majority of PsA patients, characteristic skin lesions precede the onset of articular inflammation (1, 2) . The clinical presentation is heterogeneous in nature, affecting both the peripheral and axial joints. Other frequent manifestations include enthesitis and dactylitis (2) (3) (4) . The clinical course of PsA is variable, but it is estimated that~50% of patients will develop erosive arthritis within 1 year of presentation, if left untreated (2, 4) . In addition, osteoporosis is prevalent in PsA patients, contributing to a higher risk of incidental fractures in this population (5, 6) .
Insight into the etiology and pathogenesis of psoriasis and PsA has significantly advanced over time. Consequently, multiple signaling pathways and cell populations have been implicated in the disease pathogenesis (7) . Since their initial characterization as a discrete subset of CD4+ T helper lymphocytes, Th17 cells have been shown to play a critical role in many autoimmune and chronic inflammatory diseases, including psoriasis and PsA (8) (9) (10) ). Th17 differentiation is driven by cytokines such as transforming growth factor b (TGFb), interleukin-6 (IL-6), and IL-23, resulting in the phosphorylation of Smad and STAT-3 and subsequent retinoic acid receptorrelated orphan nuclear receptor ct (RORct) transcription (11) . Th17 cells are enriched in the skin lesions of patients with psoriasis, where they promote an inflammatory response through their signature cytokines (i.e., IL-17 and IL-22). IL-17 induces chemokine production by epithelial cells, attracting neutrophils to the sites of inflammation, while IL-22 stimulates hyperproliferation of keratinocytes in diseased skin and hyperproliferation of synovial fibroblasts in the joints (10, 12) .
In patients with PsA, Th17 cells are not only enriched in cutaneous lesions, but also notably increased in the synovium (13) . Consistent with these findings, genome-wide association studies have frequently linked single-nucleotide polymorphisms in genes critical to Th17 differentiation (IL23A, IL23R, and STAT3) and those that play a role in Th17 effector cell function (IL17RD, IL22, and IL21) to the pathogenesis of psoriasis and PsA (14) . These observations have established the importance of the IL-23/Th17 axis in PsA (15) .
In addition, biologic therapies targeting IL-23 signaling, Th17 cell differentiation, and the functional cytokines of this lineage have been successful in ameliorating the symptoms of psoriatic arthritis, providing a great alternative to treatments targeting the tumor necrosis factor (TNF) signaling pathway. In particular, monoclonal antibodies against the p40 subunit of IL-12/ IL-23 (ustekinumab) or the p19 subunit of IL-23 (guselkumab), IL-17A-neutralizing antibodies (secukinumab, ixekizumab), and IL-17 receptor-blocking antibodies (brodalumab) have all been approved by the US Food and Drug Administration (FDA) and have shown great promise in the alleviation of symptoms of psoriasis and PsA (16, 17) , further highlighting the contribution of the IL-23/Th17 axis to disease pathogenesis (18) .
In this report, we describe a novel animal model of PsA driven by an augmented Th17 response downstream of T cell-specific expression of a hyperactive Stat3C allele (19 
MATERIALS AND METHODS
Mice. All experimental mice were housed under specific pathogen-free conditions in the NYU Langone Medical Center Skirball animal facility or The Jackson Laboratory. All experimental procedures and protocols were approved by the Institutional Animal Care and Use Committee. More details on the generation of these mice and specific study techniques used are available in Supplementary Methods (on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/ 10.1002/art.40447/abstract).
Quantification of the psoriasis phenotype in the mouse model. Weekly phenotype scoring, conducted by investigators who were blinded with regard to genotype, was performed. The skin phenotype was assessed in each mouse by assigning a skin phenotype score of 0-3, where a score of 0 indicates the skin appearance of a wild-type C57BL/6 mouse, score of 1 indicates thinning body hair, dry tail, or dry ears, score of 2 indicates hair loss on either the back or the head or dry skin, and score of 3 indicates >50% hair loss or very dry or crusty skin.
Anti-IL-17A antibody treatment. The neutralizing anti-IL-17A antibody was injected intraperitoneally into pregnant female mice and continued until the offspring had reached 10 days of age. The treatment was then performed on the offspring directly until they reached~8 weeks of age; the mice were then euthanized for experimental analysis. A dose of 100 lg anti-IL-17A antibody (17F3; BioxCell) was given to pups between 10 days old and 21 days old, while pregnant female mice and pups older than age 21 days were given 200 lg anti-IL-17A antibody per injection. The mice were treated twice per week. Control animals either received isotype control (MOPC-21; BioxCell) or were left untreated.
Statistical analysis. Statistical analyses were performed using unpaired, nonparametric Mann-Whitney U tests or the Sign test (when comparing normalized values). More than 3 independent experiments were performed in each analysis, unless stated otherwise. Data are presented as the mean AE SEM. P values less than or equal to 0.05 were considered significant.
RESULTS

Development of spontaneous psoriasiform skin lesions in R26Stat3C
stopfl/fl CD4Cre mice. To examine whether STAT3 hyperactivity in T cells is sufficient to drive Th17-associated disease (e.g., psoriasis), we utilized a mouse model in which the conditional allele of the hyperactive Stat3 gene, Stat3C, was expressed selectively in T lymphocytes (21) . These mice began to display a diseased skin phenotype at~5 weeks of age, with thinning body hair and dry skin observed on their ears and tails. As the mice aged, they developed focal hair loss with dry and flaky skin, mirroring the phenotype of cutaneous psoriatic lesions ( Figures 1A and B) . Disease severity varied from mild dry skin to nearly complete loss of hair on some animals (Supplementary Figure 1, retained nuclei in keratinocytes of the stratum corneum, and evidence of an increase in the number of CD3+ T cells tracking the epidermal-dermal border ( Figure 1C ). Flow cytometry analysis of the immune infiltrate showed an~20-fold increase in the percentage of CD3+CD4+ T lymphocytes in the skin of R26Stat3C stopfl/fl CD4Cre mice compared to control mice ( Figure 1D ), thus reaffirming the histologic observations.
To assess the subtype of CD4+ T cells and to evaluate their effector function, intracellular cytokine staining was performed. These experiments revealed a significantly higher percentage of IL-17, IL-22, and IL-17/IL-22 double-producing T helper cells among skin-infiltrating lymphocytes in R26Stat3C stopfl/fl CD4Cre mice compared to controls ( Figures 1E and F) . Enrichment of Th17 cells in the skin was consistent with previous findings in patients with psoriasis (2) . In addition, levels of both Th1 and Th2 cytokines were reduced in the skin of R26Stat3C Finally, cell clusters with an appearance similar to that of Munro's micro-abscesses, a pathologic hallmark of inflammatory psoriasis, were observed in the skin of R26Stat3C stopfl/fl CD4Cre mice ( Figure 1C ). Munro's micro-abscesses are characterized by a large infiltration of neutrophils. A significant increase in neutrophil abundance was indeed evident in the enzymatically digested skin of R26Stat3C stopfl/fl CD4Cre mice, as revealed by flow cytometry ( Figure 1G ).
Evidence of tendon inflammation, joint erosion, and osteopenia in conjunction with psoriasiform skin lesions in R26Stat3C stopfl/fl CD4Cre mice. Up to 30% of patients with psoriasis develop arthritis within 7 years of disease incidence (2) . Although some genetic and clinical risk factors have been established, the underlying etiology of this progression remains to be elucidated. Even though gross inspection of R26Stat3C stopfl/fl CD4Cre mice did not reveal obvious joint swelling, we aimed to examine the joints of these animals thoroughly, since there are similarities between the skin phenotype observed and the clinical hallmarks of psoriatic lesions. It has been proposed that articular inflammation in PsA begins in the tendons and entheses, with enthesitis being a unique feature of PsA and related spondyloarthritis (22, 23) .
To investigate whether R26Stat3C stopfl/fl CD4Cre mice develop enthesitis or tendinitis, we collected RNA from the Achilles tendons of R26Stat3C stopfl/fl CD4Cre mice and their littermate controls. Quantitative polymerase chain reaction was performed to examine the expression of messenger RNA (mRNA) for several inflammatory genes. Figure 3B ). These data suggest that a low-grade inflammation was present in the synovio-entheseal compartments of these animals.
To further inspect and characterize the ankle joints of R26Stat3C stopfl/fl CD4Cre mice, we performed histopathologic analysis. Staining of the ankle joints with hematoxylin and eosin and Giemsa revealed infiltration and accumulation of cells in the Achilles tendons of R26Stat3C stopfl/fl CD4Cre mice, but not in control animals ( Figure 2B and Supplementary Figure 3C [http:// onlinelibrary.wiley.com/doi/10.1002/art.40447/abstract]). We also observed clusters of cells accumulating at the entheseal tissue in some R26STAT3C stopfl/fl CD4Cre mice (Supplementary Figure 3C) .
We then performed immunofluorescence analysis using an anti-CD3 antibody, which revealed infiltration of T cells to the tendons in the ankle joints of R26Stat3C stopfl/fl CD4Cre mice ( Figure 2C ). In addition to enthesitis, we observed synovitis in the footpad regions of R26Stat3C stopfl/fl CD4Cre mice ( Supplementary Figure 4 , http://onlinelibrary.wiley.com/doi/10.1002/art.40447/ abstract). The data from immunofluorescence analysis again validated our findings of infiltration of CD3+ T lymphocytes to these sites of inflammation (Supplementary Figure 4) . In addition to the ankle joint, we observed tertiary lymphoid organ-like structures in the infrapatellar fat pad beneath the patella tendon of R26Stat3C CD4Cre mice spontaneously developed tendinitis, enthesitis, and synovitis, whereas these features were absent in control animals.
To investigate whether infiltration of the joints with inflammatory cells in R26Stat3C stopfl/fl CD4Cre mice was accompanied by cartilage and bone erosion or remodeling, we performed microfocal computed tomography (micro-CT) to look at periarticular bone density in these animals. Reduction in bone density was clearly seen in the knees of R26Stat3C stopfl/fl CD4Cre mice, whereas we did not observe consistent changes in the cartilage. Specifically, we observed a loss of subchondral bone in the femur and tibia ( Figure 2D ). Bone erosion was also observed at the metacarpophalangeal and interphalangeal joints of R26Stat3C stopfl/fl CD4Cre mice ( Figure 2D ). In addition to peripheral arthritis, R26Stat3C stopfl/fl CD4Cre mice also displayed deformity along the spine. These mice often presented a hunched posture reminiscent of kyphosis, and data from micro-CT analysis showed erosive destruction to their vertebral bodies ( Figure 2E ). This suggested that inflammation occurs both in the peripheral joints and in the axial joints of R26Stat3C stopfl/fl CD4Cre mice.
In addition to the articular defects observed, the R26Stat3C stopfl/fl CD4Cre mice presented a severe osteopenia phenotype. Skeletal bones of the R26Stat3C stopfl/fl CD4Cre mice were notably small and more fragile than those from littermate controls. These observations were further substantiated by the bone mineral density measurements obtained with a dual x-ray absorptiometry scanner ( Figure 2G and Supplementary Figure 6A [http://onlinelib rary.wiley.com/doi/10.1002/art.40447/abstract]). Micro-CT analysis of the femurs of R26Stat3C stopfl/fl CD4Cre mice also showed a reduction in both trabecular and cortical bone thickness in these animals ( Figures 2F and H) . Overall, we found that R26Stat3C stopfl/fl CD4Cre mice exhibited many key features of PsA-a psoriatic skin phenotype, arthritis in multiple joints, and osteopeniathus making these mice an excellent model for this inflammatory disease. CD4Cre mice was sufficient to promote inflammatory responses in the skin and synovio-entheses of these mice (as shown in Figures 1 and 2) . Immunohistologic analysis also revealed an increase in the percentage of CD3+ T cells in the bones of R26Stat3C stopfl/fl CD4Cre mice ( Figure 3A) . Flow cytometry analysis of leukocytes from the bone marrow of R26Stat3C stopfl/fl CD4Cre mice similarly revealed an enrichment of IL-17-and/or IL-22-producing T cells in the bone marrow ( Figure 3B ).
Beyond their established role in the skin and musculoskeletal inflammation, Th17 cells have been ascribed osteoclastogenic properties in PsA (26) . Concurrent with the increase in the Th17 population, the percentages of other subsets of T helper cells, including Th1, Th2, and regulatory T cells, were reduced in the bone marrow of R26Stat3C stopfl/fl CD4Cre mice (Supplementary Figures 7A-C , http://onlinelibrary.wiley. com/doi/10.1002/art.40447/abstract). These subsets of T cells were postulated to inhibit osteoclastogenesis through the effector molecules they secreted (27) . We hypothesized that changes in the bone-resorbing osteoclast cell population might be a causal factor in the osteopenia phenotype observed in R26Stat3C stopfl/fl CD4Cre mice.
To confirm this, we first performed a conventional 10-day in vitro osteoclast differentiation assay using the bone marrow of R26Stat3C stopfl/fl CD4Cre mice and their stopfl/fl CD4Cre and control mice. In C and D, results are the mean AE SEM of ≥6 mice (ages 6-10 weeks) per genotype; data are representative of ≥3 independent experiments. ** = P ≤ 0.01; *** = P ≤ 0.001; **** = P ≤ 0.0001, by Sign test in C and by nonparametric 2-tailed Mann-Whitney U test in D. NS = not significant.
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littermate controls. Consistently, bone marrow from the R26Stat3C stopfl/fl CD4Cre mice differentiated into more osteoclasts than were observed in the bone marrow from control mice, as identified by tartrate-resistant acid phosphatase (TRAP) staining (Figures 3C and D) . Moreover, a higher number of osteoclasts were observed in the bones of the R26Stat3C stopfl/fl CD4Cre mice than in the bones of control animals, as revealed by immunostaining of femur sections for cathepsin K ( Supplementary Figure 6B , http://onlinelibrary.wiley.com/doi/10.1002/art. 40447/abstract).
In order to better quantify the number of osteoclasts in vivo, we performed flow cytometry analysis on mouse bone marrow. Although there are no reliable markers of mature osteoclasts that can be utilized in fluorescence-activated cell sorting analysis, we were able to evaluate the frequency of OCP cells in the mouse bone marrow, a cell population that has previously been described as CD3ÀCD19ÀTer119À(lineage-negative)CD11b low/À ,Ly6C+ cells (28) . The monocyte/macrophage markers used to identify this progenitor population reflect the putative myeloid lineage cell origin of osteoclasts. The bone marrow of R26Stat3C stopfl/fl CD4Cre mice was found to contain a higher percentage of OCP cells, as determined by flow cytometry ( Figure 3E ).
To validate whether these cells were true OCPs, we sorted the OCP cells and other non-OCP cell populations Figure 3F ). These data suggest that augmented Th17 responses in R26Stat3C stopfl/fl CD4Cre mice may lead to an accumulation of OCPs and enhanced production of RANKL in the bones, contributing to the osteopenia phenotype observed in these animals.
Having found striking differences in osteoclasts, we also aimed to examine the differentiation of osteoblasts in the bone marrow of R26Stat3C stopfl/fl CD4Cre mice, since the homeostasis of bone remodeling is governed both by bone-resorbing osteoclasts and by bone-building osteoblasts. Bone marrow cells from R26Stat3C stopfl/fl CD4Cre mice failed to develop into proper osteoblasts in in vitro assays (Supplementary Figure 8B , http://onlinelibrary.wiley.com/doi/10.1002/art. 40447/abstract). These data suggest that the osteopenia present in the R26Stat3C stopfl/fl CD4Cre mice was caused by a disturbance of the dynamic homeostasis in bone remodeling, with a concomitant loss of osteoblasts and augmented differentiation of osteoclasts.
Amelioration of the psoriasis phenotype with neutralizing antibodies against IL-17 and ablation of IL-22. Given the large increase in the levels of IL-22 and IL-17 that we observed in the skin and bones of R26Stat3C stopfl/fl CD4Cre mice, we interrogated whether reduction or elimination of these cytokines would ameliorate the disease phenotype. We monitored the skin of the mice prior to euthanizing them, to determine whether treatment could alter the course of disease progression. Treatment of mice with an anti-IL-17 neutralizing antibody resulted in a delay of phenotype progression ( Figure 4A ), thereby representing an important corollary to human disease in that several therapeutic agents targeting the IL-17 pathway have been approved by the FDA for the treatment of patients with psoriasis or PsA, resulting in notable clinical outcomes (30, 31) . The improvement in phenotype was additionally observed in histologic sections of the mouse skin, since treatment with anti-IL-17 restored epidermal thickness to control levels ( Figure 4B) .
Similarly, genetic ablation of IL22 also delayed the progression of psoriatic disease, arguably to a greater extent than that achieved with IL-17 blockade, as judged by the disease severity score and histologic evaluation ( Figures 4A and B mice had decreased ( Figure 5D ). Thus, Th17 cells induced osteoclastogenesis, at least in part, through the promotion of an increase in the numbers of OCP cells and RANKL producers in the bones.
DISCUSSION
PsA is a debilitating disease with a molecular mechanism that has yet to be fully elucidated. In an effort to understand the etiology of this disease, several mouse models of PsA have been put forward in prior studies, but none have thoroughly recapitulated the complex and heterogeneous manifestations of disease symptoms. For example, keratinocyte-specific deletion of JunB and c-Jun genes, which are found in the psoriatic susceptibility locus PSORS6 (19p13), led to psoriatic-like skin lesions and arthritis in the extremities in a mechanism involving TNF and lymphocytes (32) . However, the description of this mouse phenotype did not address the joint inflammation common to human patients with PsA, and there have not been any follow-up reports investigating articular inflammation in this model. In other models, such as in aging DBA/1 mice or mice instilled with mini-circle IL-23, the mice developed spondyloarthropathy but were devoid of psoriasis (24, 33) . A further shortcoming of the DBA/1 mouse model was that, whereas PsA affects females and males equally in human patients, only aged male DBA/1 mice developed arthritis. In addition to genetic manipulation, application of the Toll-like receptor 7 agonist imiquimod could trigger psoriatic skin lesions in mice, and although this model was highly useful for studies of psoriasis pathogenesis, the treatment failed to induce arthritis (34) .
Recently, it was shown that skin and joint inflammation could manifest following intraperitoneal injection of carbohydrate mannan from Saccharomyces cerevisiae (35) . In that model, the contribution of conventional a/b T cells and B cells to the disease was entirely dispensable, whereas IL-17 from c/d T cells alone was sufficient to drive PsA-like phenotypes. The model highlighted the important role of c/d T cells in skin inflammation, but the phenotype was more akin to systemic shock-induced responses rather than a chronic inflammatory disease.
Herein we present R26Stat3C stopfl/fl CD4Cre mice as a new model with several features of PsA, in which the mice spontaneously developed psoriatic skin lesions, accompanied by inflammatory infiltrates in multiple joints, with associated periarticular bone erosion and severe osteopenia. The R26Stat3C stopfl/fl CD4Cre mice presented most of the phenotypes found in patients with PsA in a fully penetrant manner, without deliberate triggers, despite the mutant Stat3 expression being limited exclusively to the T cell lineage. Previously, Sano et al demonstrated that ectopic expression of Stat3C in keratinocytes is sufficient to drive psoriasis (36) . Furthermore, expression of Stat3C in keratinocytes using K5-Stat3C, together with a global expression of F759 mutant gp130 allele, led to the development of both skin and joint inflammation, reminiscent of that in patients with PsA. Taken together, these results highlight the importance of STAT-3 signaling in the continuum of psoriasis pathogenesis.
In addition, R26Stat3C stopfl/fl CD4Cre mice developed the PsA phenotype in response to perturbation in the IL-23/Th17 axis, whose role in the pathogenesis of PsA has been established (15, 26) . In the R26Stat3C stopfl/fl CD4Cre mouse model, this signaling pathway was augmented by expression of a hyperactive Stat3 gene selectively in T lymphocytes. Stat3C dimerized in response to IL-6 receptor signaling, which is crucial for Th17 differentiation (37). Genome-wide association studies have demonstrated an association between STAT3 and susceptibility to PsA (20) . Therefore, in R26Stat3C stopfl/fl CD4Cre mice, several features of the phenotype, as well as the underlying disease mechanisms of PsA, were mimicked.
Of utmost importance to the field is the fact that enthesitis is present in one-third of patients with PsA, including inflammation of the Achilles tendons, plantar fascia, and lateral epicondyles (38) . The presence of enthesitis is part of the classification criteria for PsA, but its clinical diagnosis remains very challenging (39, 40) . This leads to underappreciation of the early phases of the disease and a concomitant suboptimal treatment during the timeframe of active inflammation, whereas current therapies could potentially alter the natural history of this process. Indeed, several groups have stressed the role of the entheses as an initiating site of inflammation in a proportion of PsA patients who go on to develop synovitis and destructive arthritis (23, (40) (41) (42) . However, very little is known about the biology and molecular mechanisms by which proinflammatory resident cells can drive downstream systemic effects. Our finding that Stat3 hyperactivity in the T cells was sufficient to promote concomitant 864 YANG ET AL inflammation in the skin and synovio-entheses of these mice adds insight into the disease pathogenesis and suggests that Th17 cells are central to this early manifestation of PsA. PsA is a multiorgan chronic inflammatory disease that affects patients' skin, ligaments, joints, and bones. A severe and common comorbidity in patients with PsA is osteoporosis. Homeostasis in the bone is well maintained by distinct cell populations, including osteoclasts that resorb bone and osteoblasts that promote bone formation. Imbalance between these populations can reduce bone mineral density, leading to osteopenia. When we analyzed the bones of R26Stat3C stopfl/fl CD4Cre mice, we observed an increase in the CD3ÀCD19ÀTer119ÀC-D11 low Ly6C high cell population, a subset that has been demonstrated to represent OCP cells (28) . Blood samples from patients with PsA that had started developing bone erosions exhibited an increased population of CD14+ OCP cells (43) . Interestingly, CD14+ monocytes in humans were found to correspond to Ly6C+ myeloid cells in mice (44) , and there was an increased proportion of OCPs in the bones of R26Stat3C stopfl/fl CD4Cre mice with high expression of the Ly6C surface marker.
Our study of R26Stat3C stopfl/fl CD4Cre mice allowed us to probe the cells directly from the bones and to further investigate the mechanism behind the changes locally. These OCP cells differentiated into bone-resorbing osteoclasts upon exposure to cytokines such as RANKL. Although it was proposed that Th17 cells could express RANKL, which directly activates differentiation of OCPs (27) , we demonstrated that the increase in RANKL-producing cells in our mouse model was restricted to the CD45À cell population in the bones. This suggests that an indirect pathway plays a role in this process, where IL-17 from Th17 cells acts on mesenchymal cells, including osteoblasts and fibroblasts, which then up-regulate the expression of RANKL to drive osteoclast differentiation. Besides the promotion of osteoclastogenesis, defects in osteoblast differentiation, as observed in the bone marrow from R26Stat3C stopfl/fl CD4Cre mice, suggested that Th17 cytokines have a suppressive role in these bone-forming cells, consistent with recent observations by Wagner and colleagues, who recently demonstrated in 2 murine models of psoriasis that IL-17 suppressed the differentiation of osteoblasts and osteocytes (45).
Although disease-modifying antirheumatic drugs are still the first-line choice when treating patients with PsA, biologic therapies have revolutionized the field, due to their high efficacy and safety profile. TNF antagonists, including monoclonal antibodies and fusion proteins, are the most commonly used biologic agents and the first to be approved by the FDA for treating PsA. Biologics targeting the IL-23/IL-17 axis have gained interest in recent years. Ustekinumab, which targets the p40 subunit of both IL-12 and IL-23 cytokines, and a monoclonal antibody against IL-17 (secukinumab) have each shown promising therapeutic outcomes and have also been approved by the FDA for the treatment of PsA (46, 47) . Because of the heightened Th17 response observed in the R26Stat3C stopfl/fl CD4Cre mice, we decided to mimic such treatment with the use of a neutralizing antibody against IL-17. Anti-IL-17 treatment reversed the progression of the psoriatic skin lesions in R26Stat3C stopfl/fl CD4Cre mice and partially improved the osteopenia phenotype. This finding confirmed the efficacy of biologics in targeting one of the central signaling pathways contributing to PsA pathogenesis.
Furthermore, elimination of IL-22 led to amelioration of the skin and bone phenotype in R26Stat3C stopfl/fl CD4Cre mice, reinforcing the potential importance of this cytokine in driving disease pathogenesis, suggesting that this cytokine may also play a central role in the pathogenesis of PsA. R26Stat3C stopfl/fl CD4Cre IL-22 À/À mice did have a considerable reduction in RANKL-producing cells in their bones. This was noteworthy since IL-17 is known to promote RANKL expression. However, the role of IL-22 in osteoclastogenesis is less appreciated. IL-22 was previously shown to stimulate RANKL expression in synovial fibroblasts obtained from rheumatoid arthritis patients, and fibroblasts pretreated with IL-22 could stimulate the differentiation of osteoclasts from monocytes in the absence of exogenous RANKL (48) . Both the results of that study and our observations of the reduction in RANKL-producing cells in R26Stat3C stopfl/fl CD4Cre IL-22 À/À mice indicate that both IL-22 and IL-17 appear to contribute to osteoclastogenesis.
In addition to our observations of skin, synovioentheseal, and bone inflammation in R26Stat3C stopfl/fl CD4Cre mice, a heavy immune cell infiltration in the lung is also characteristically found in this model (21) , with little or no inflammation at other sites. We have previously identified infiltration of neutrophils and chemokine up-regulation as characteristics that lead to lung function impairment in R26Stat3C stopfl/fl CD4Cre mice (21) . These lung defects likely contribute to the short lifespan of these mice (duration of 8-12 weeks, depending on the facility). This limited lifespan may also explain why we have yet to observe full-blown inflammation in the joints of these mice. The mechanisms at play that direct Th17-mediated infiltration at only these distinct sites, namely, the skin, joints, bone, and lung, remain to be elucidated.
There are still many questions unanswered in the field of PsA, and one obstacle has been the lack of an accurate animal model. The R26Stat3C stopfl/fl CD4Cre animal model faithfully recapitulates many of the clinical features of PsA to a degree that other models have failed to capture. The disease manifestation was spontaneous, highly penetrant, and driven by a genetic perturbation relevant to human disease. As such, this murine model provides an excellent platform for further studies examining the role of additional genetic and environmental triggers in PsA, and is a useful addition to the repertoire of preclinical animal models of this rheumatic disease.
